Centessa Pharmaceuticals (NASDAQ:CNTA) Rating Lowered to “Hold” at B. Riley Financial

Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by B. Riley Financial from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other research analysts also recently issued reports about the company. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday. Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Oppenheimer lifted their price target on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $40.00.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $39.86 on Tuesday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a twelve month low of $9.60 and a twelve month high of $40.26. The stock has a market capitalization of $5.82 billion, a P/E ratio of -21.78 and a beta of 1.25. The company has a 50 day moving average of $26.62 and a 200-day moving average of $25.35.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Monday, April 6th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). As a group, equities research analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other news, insider Iqbal J. Hussain sold 38,951 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Karen M. Anderson sold 120,029 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.25, for a total value of $3,150,761.25. Following the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,629,731.25. This trade represents a 65.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 349,073 shares of company stock worth $9,429,412. Insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $80,000. T. Rowe Price Investment Management Inc. lifted its position in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after purchasing an additional 1,516 shares during the period. Coastal Bridge Advisors LLC grew its stake in Centessa Pharmaceuticals by 7.1% during the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after buying an additional 931 shares in the last quarter. XTX Topco Ltd bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $1,978,000. Finally, Voloridge Investment Management LLC bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $8,710,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Key Stories Impacting Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to acquire Centessa for $38 cash per share plus a contingent value right worth up to ~$9, valuing the deal up to ~$7.8B — the takeover premium is the main upward driver for CNTA. Lilly to acquire Centessa — CNBC
• Positive Sentiment: Unusually large call-option purchases have been reported (multiple days of elevated call volume), indicating speculative/leveraged bullish positioning around the deal and near-term upside. High volume call options — AmericanBankingNews
• Neutral Sentiment: Leerink Partners reaffirmed a “market perform” rating and raised its price target to $40 (from $36) — a modest endorsement but effectively sets expectations near the deal price. Leerink reaffirmation — Benzinga
• Negative Sentiment: Several sell-side firms (Wolfe Research, Needham, Stephens and others) have downgraded CNTA to Hold from higher ratings this week — analyst downgrades can increase selling pressure and reduce conviction among non-deal investors. Wolfe downgrade — AmericanBankingNews
• Negative Sentiment: Multiple law firms have launched investigations and shareholder class-action alerts assessing whether the sale price/process is fair to public shareholders — heightened legal/transaction risk can weigh on sentiment and vote outcomes. Shareholder investigation — PR Newswire
• Negative Sentiment: Large put-option purchases were also reported (very high put volume on 4/1), and the company last reported an EPS miss for the quarter — both signal hedging/speculation to the downside and highlight operational/earnings weakness.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.